Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Targeting CD33+ acute myeloid leukemia with GLK-33, a lintuzumab-auristatin conjugate with a wide therapeutic window.
Satomaa T, Pynnönen H, Aitio O, Hiltunen JO, Pitkänen V, Lähteenmäki T, Kotiranta T, Heiskanen A, Hänninen AL, Niemelä R, Helin J, Kuusanmaki H, Vänttinen I, Rathod R, Nieminen AI, Yatkin E, Heckman CA, Kontro M, Saarinen J. Satomaa T, et al. Among authors: kotiranta t. Mol Cancer Ther. 2024 Apr 2. doi: 10.1158/1535-7163.MCT-23-0720. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38561023
Trastuzumab-MMAU Antibody-Auristatin Conjugates: Valine-Glucoserine Linker with Stabilized Maleimide Conjugation Improves In Vivo Efficacy and Tolerability.
Goldberg SD, Satomaa T, Aina O, Aitio O, Burke K, Dudkin V, Geist B, Irrechukwu O, Hänninen AL, Heiskanen A, Helin J, Hiltunen JO, Kinyamu-Akunda J, Klein DM, Kohli N, Kotiranta T, Lähteenmäki T, Niemelä R, Pitkänen V, Pynnönen H, Rittase W, Wiley K, Zhou J, Saarinen J. Goldberg SD, et al. Among authors: kotiranta t. Mol Cancer Ther. 2024 Feb 7. doi: 10.1158/1535-7163.MCT-23-0591. Online ahead of print. Mol Cancer Ther. 2024. PMID: 38324296